or Try an Advanced Search...

    Technical Analysis for ZNTL - Zentalis Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 11.98 2.61% 0.31
    ZNTL closed up 2.61 percent on Wednesday, May 15, 2024, on 80 percent of normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Flat
    Historical ZNTL trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Gapped Up Strength 0.00%
    20 DMA Resistance Bearish 2.61%
    Gapped Up Strength 2.61%
    Bearish Engulfing Bearish 1.91%
    Fell Below 20 DMA Bearish 1.91%
    180 Bearish Setup Bearish Swing Setup 1.91%
    Outside Day Range Expansion 1.91%
    20 DMA Support Bullish -4.51%
    Up 3 Days in a Row Strength -4.51%
    Older End-of-Day Signals for ZNTL ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % about 14 hours ago
    Gap Up Closed about 15 hours ago
    60 Minute Opening Range Breakdown about 15 hours ago
    Fell Below Previous Day's Low about 15 hours ago
    Down 1% about 15 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ZNTL Chart by TradingView
    Basic chart:

    Profile

    Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin Bunker on December 23, 2014 and is headquartered in New York, NY.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Hormones Her2 Her2/Neu Transcription Factors Estrogen Molecule Therapeutics Antiestrogens Estrogen Receptor Receptor Positive Selective Estrogen Receptor Degraders Intracellular Receptors Metastatic Breast Cancer

    Is ZNTL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 14 Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
    May 8 Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock
    May 8 Zentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic ...
    May 7 Zentalis Pharmaceuticals GAAP EPS of $0.14, revenue of $40.56M
    May 7 Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
    Apr 12 Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
    Apr 11 Zentalis Pharmaceuticals says Melissa Epperly resigns as CFO
    Apr 2 Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
    Mar 1 Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Feb 29 Zentalis files automatic mixed securities shelf
    See more ZNTL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 31.46
    52 Week Low 9.56
    Average Volume 735,650
    200-Day Moving Average 16.22
    50-Day Moving Average 13.41
    20-Day Moving Average 11.92
    10-Day Moving Average 11.97
    Average True Range 0.99
    RSI (14) 45.36
    ADX 17.9
    +DI 14.46
    -DI 15.79
    Chandelier Exit (Long, 3 ATRs) 10.50
    Chandelier Exit (Short, 3 ATRs) 13.35
    Upper Bollinger Bands 13.19
    Lower Bollinger Band 10.65
    Percent B (%b) 0.52
    BandWidth 21.28
    MACD Line -0.38
    MACD Signal Line -0.49
    MACD Histogram 0.111
    Fundamentals Value
    Market Cap 847.42 Million
    Num Shares 70.8 Million
    EPS -4.56
    Price-to-Earnings (P/E) Ratio -2.63
    Price-to-Sales 0.00
    Price-to-Book 1.69
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 13.51
    Resistance 3 (R3) 13.49 12.97 13.25
    Resistance 2 (R2) 12.97 12.58 12.97 13.16
    Resistance 1 (R1) 12.47 12.33 12.21 12.49 13.08
    Pivot Point 11.95 11.95 11.81 11.95 11.95
    Support 1 (S1) 11.45 11.56 11.19 11.47 10.87
    Support 2 (S2) 10.93 11.31 10.93 10.79
    Support 3 (S3) 10.43 10.93 10.70
    Support 4 (S4) 10.45